Abdi İbrahim Pharmaceuticals

Abdi İbrahim, the Turkish pharmaceutical industry leader, was founded at a small pharmacy in 1912 in Küçükmustafapaşa, Istanbul, by pharmacist Abdi İbrahim Bey. Abdi İbrahim has the largest product portfolio in the sector, with nearly 200 brands and more than 400 products which it develops itself as well as working with 30 licensors.

With its powerful vision, dynamic structure and contemporary outlook, Abdi İbrahim has been the leader of Turkey’s pharmaceutical industry since 2002. Today, Abdi İbrahim, which operates in 14 countries outside Turkey, exports to more than 60 countries ranging from Canada to European Union member states, from North Africa to Asia, and is the largest employer in the Turkish pharmaceutical industry with 4.600 qualified employees. The company also leads with its marketing and sales team, which is the largest in the industry.

Abdi İbrahim, which has the first accredited R&D centre in the industry, is a role model with its technological equipment and architecture as well as its R&D processes for future healthcare.

As well as its R&D Centre, Abdi İbrahim has a manufacturing facility for chemical products, Turkey's largest biotechnological manufacturing facility AbdiBio, a hormone production facility, a sterile ophthalmology and sterile inhalation products production facility, and a sterile injectable and oncology products production facility which will be operational in 2023 in Istanbul’s Esenyurt production complex. Abdi İbrahim has also R&D centres and production facilities in Kazakhstan and Algeria.

Abdi İbrahim was part of the Swiss joint venture that acquired OM Pharma, an 83-year-old pharma company based in Switzerland, one of the leading countries in the pharmaceutical industry, in 2020. After the acquisition, Abdi İbrahim owned a 28.5 percent stake in OM Pharma. The acquisition made Abdi İbrahim the first and only Turkish pharma company to form a strategic partnership with a European counterpart. Abdi İbrahim was also the only foreign partner in the joint venture that acquired OM Pharma. Abdi İbrahim has added to its investments with the acquisition of a 90% share of INOLIVA, a company operating in the Turkish health sector that has rapidly made its mark on the market with its innovative products.

With its “Rational Medicine Use Campaign”, initiated in its 100th year of operation, Abdi İbrahim aims to raise social awareness and achieve long term behavioural change in unconscious medicine use, which has a high impact on public health and the country’s economy.

In 2015, Abdi İbrahim renovated the health museum in Dar al-Shifa’, focusing on Ottoman medicine from the 15th to the 18th century, making the treasures of our medical history accessible to the public. The Sultan Bayezid II Edirne Hospital Restoration Project has been achieved 6 awards.

Abdi İbrahim took an important step by signing United Nations Global Principles Agreement in 2010, creating the opportunity to share the high standards which it has achieved in the fields of human rights and environmental and social responsibility. Abdi İbrahim has also focused on its sustainability activities through Level A of the Global Reporting Initiative.

As a corporate citizen working towards creating a better world and a better future, adhering to its mission in the sector and to the requirements of societal priorities, Abdi İbrahim focuses on sustainability in all its business processes. Approaching all of its actions from the standpoint of environmental, social and governance (ESG) criteria, Abdi İbrahim has made it possible to gauge the company’s performance not only on the basis of positive financial results, but also from the perspective of its positive impact on the community and the environment.

Stepping forward in the area of maintaining sustainability as a part of its process of green transformation, Abdi İbrahim upholds the European Green Deal and the Sustainable Development Goals (SDGs) adopted by the United Nations, and also relies upon processes such as Corporate Prioritization Analysis and Organizational Life Cycle Analysis (O-LCA) to achieve improvements in all its business processes in the light of its many sustainability projects.

As from 2020, Abdi İbrahim became the first pharmaceuticals company in Turkey to use 100 percent renewable energy, with solar and wind energy plants that meet the energy needs of all its facilities and buildings. Making significant strides to reduce its carbon footprint, Abdi İbrahim’s goal is to become a carbon neutral company by 2030.

Placing great importance on the matter of water sustainability, Abdi İbrahim is the first Turkish pharmaceuticals company to join the signatories of the CEO Water Mandate, an initiative of the United Nations Global Compact. Becoming the first Turkish company to sign the ‘Science-based Targets Initiative (SBTI)’ and the first and only Turkish company to align with the Recover Better Declaration founded under the leadership of the SBTI. Abdi İbrahim has also added to this prestige by becoming a member of the Carbon Disclosure Project (CDP). In its first reporting in the context of Climate Change and Water Safety Programmes, the company has earned eligibility to join the B- list of companies with above average global performance.

A force for healing in a changing world, Abdi İbrahim increases its effectiveness in international markets with each passing day. Its vision for 2025 - apart from maintaining its status as a wholly local company - is to become "one of the top 100 pharmaceutical companies in the world".